our Premium Content: News alerts, weekly reports and conference planners

GENE:

MAPK11 (Mitogen-Activated Protein Kinase 11)

News alerts, weekly reports and conference planners

2ms

Four-dimensional data independent acquisition proteomics and metabolomics reveal mechanisms of hydrogen-rich water at Zusanli (ST36) point against triple-negative breast cancer in mice. (PubMed, J Tradit Chin Med)

The injection of hydrogen-rich water into the Zusanli (ST36) acupoint effectively inhibited the hyperplasia of 4T1 BC cells and enhanced their apoptosis, potentially exerting a therapeutic effect through multiple pathways and targeting various sites.

2 months ago

Preclinical • Journal • Metabolomic study

IL6 (Interleukin 6) • MAPK1 (Mitogen-activated protein kinase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IL6ST (Interleukin 6 Signal Transducer) • NFATC1 (Nuclear Factor Of Activated T Cells 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK10 (Mitogen-Activated Protein Kinase 10)

4ms

CTTN overexpression in HNSCC inhibits Anoikis-apoptosis. (PubMed, Sci Rep)

Furthermore, we found that inhibiting the apoptosis-related gene CTTN suppresses the anti-apoptotic capacity of HNSCC. Results from HNSCC-PDOs suggest that CTTN may represent a key target for HNSCC invasion and treatment.

4 months ago

Journal

TTN (Titin) • SPP1 (Secreted Phosphoprotein 1) • PLK1 (Polo Like Kinase 1) • MAPK1 (Mitogen-activated protein kinase 1) • SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • CEACAM1 (CEA Cell Adhesion Molecule 1) • SFRP1 (Secreted frizzled related protein 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • CTTN (Cortactin) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2 ) • PLAU (Plasminogen Activator) • PTK2 (Protein Tyrosine Kinase 2) • SPHK1 (Sphingosine Kinase 1)

4ms

Exploring the pharmacological action mechanism of chamomile essential oil on the treatment of breast cancer based on network pharmacology. (PubMed, BMC Complement Med Ther)

Our research suggest that CEO inhibit proliferation of breast cancer cell lines through modulating those multi-pathways and multi-targets. The present study not only indicate the therapeutic potential of CEO for breast cancer, but also provide valuable insight into its underlying mechanism.

4 months ago

Journal

ER (Estrogen receptor) • JAK1 (Janus Kinase 1) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK14 (Mitogen-Activated Protein Kinase 14)

8ms

Machine Learning-Driven PCDI Classifier for Invasive PitNETs. (PubMed, Curr Gene Ther)

The PCDI provides a robust molecular framework for risk stratification and personalized therapy in invasive PitNETs. Future studies should validate its clinical utility and explore pancancer relevance.

8 months ago

Journal • IO biomarker

FGFR3 (Fibroblast growth factor receptor 3) • MAPK1 (Mitogen-activated protein kinase 1) • SLC7A11 (Solute Carrier Family 7 Member 11) • MAPK11 (Mitogen-Activated Protein Kinase 11)

9ms

Immunosuppressive MAP3K11 as an independent risk factor for progression-free survival promotes prostate cancer metastasis by regulating epithelial-mesenchymal transition. (PubMed, Biochem Biophys Res Commun)

Targeted inhibition of MAP3K11 resists PCa metastasis by limiting EMT onset and mobilizes immune infiltration.

9 months ago

Journal

HRAS (Harvey rat sarcoma viral oncogene homolog) • MAPK1 (Mitogen-activated protein kinase 1) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11) • MAPK11 (Mitogen-Activated Protein Kinase 11)

12ms

Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis. (PubMed, J Neurooncol)

Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation, providing novel molecular targets for glioma treatment and suggesting its therapeutic potential beyond anesthesia.

12 months ago

Journal

MAPK1 (Mitogen-activated protein kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11)

1year

Kinase Inhibitor-Induced Cell-Type Specific Vacuole Formation in the Absence of Canonical ATG5-Dependent Autophagy Initiation Pathway. (PubMed, Mol Cell Biol)

A screen for modulators of SB202190-induced vacuolation revealed molecules including multi-kinase inhibitor sorafenib as inhibitors of vacuolation and sorafenib co-treatment enhanced cytotoxicity of SB202190. To identify the factors determining the cell-type specificity of vacuolation induced by SB-compounds and VE-821, we compared the transcriptomics data from vacuole-forming and non-vacuole-forming cancer cell lines and identified a gene expression signature that may define sensitivity of cells to these small-molecules. Further analyses using small molecule tools and the gene signature discovered here, could reveal novel mechanisms regulating this interesting anti-cancer phenotype.

1 year ago

Journal

MAPK1 (Mitogen-activated protein kinase 1) • ATG5 (Autophagy Related 5) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK14 (Mitogen-Activated Protein Kinase 14)

sorafenib • VE-821 • SB202190

1year

Bryostatin-1 enhances the proliferation and functionality of exhausted CD8+ T cells by upregulating MAP Kinase 11. (PubMed, Front Immunol)

Our data demonstrate that bryostatin-1 induces a MAPK 11-dependent improvement in the proliferative and functional capacity of exhausted T cells. This study provides a rationale for bryostatin-1's potential to help eradicate the HIV reservoir during treatment, and it may also contribute to cancer immunotherapy by functionally improving exhausted CD8+ T cells.

1 year ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11)

1year

Activation of P38 MAPK Signaling Cascade is Linked with Clinical Outcomes and Therapeutic Responses in Human Cancers. (PubMed, Biochemistry (Mosc))

For instance, higher activation of the p38β and p38γ pathways was linked to positive responses to taxane and anthracycline therapies in breast cancer, while lower activation of the p38α and p38β pathways correlated with better responses to 5-fluorouracil-based treatments in colorectal cancer. However, associations with individual MAPK14, MAPK11, MAPK12, and MAPK13 gene expression levels were less robust. Hence, the p38 pathway activation levels could serve as potential biomarkers for predicting clinical outcomes and personalizing treatment strategies, including use of the selective p38 MAPK inhibitors.

1 year ago

Clinical data • Journal

HER-2 (Human epidermal growth factor receptor 2) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK12 (Mitogen-Activated Protein Kinase 12) • MAPK14 (Mitogen-Activated Protein Kinase 14)

5-fluorouracil

1year

Novel kinase regulators of extracellular matrix internalisation identified by high-content screening modulate invasive carcinoma cell migration. (PubMed, PLoS Biol)

Strikingly, MAP3K1, MAPK11, PPP2R1A, and α2 integrin expression were higher in chemotherapy-resistant tumours in breast cancer patients. Our results identified the α2β1 integrin/p38 signalling axis as a novel regulator of ECM endocytosis, which drives invasive migration and tumour progression, demonstrating that our high-content screening approach has the capability of identifying novel regulators of cancer cell invasion.

1 year ago

Journal

MAPK1 (Mitogen-activated protein kinase 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)

over1year

Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease. (PubMed, J Clin Exp Hematop)

Particularly, upregulated IL33 expression was demonstrated for the first time in iMCD-TAFRO/NOS. Thus, inflammatory signaling, such as JAK-STAT and MAPK, may be enhanced in iMCD-TAFRO/NOS and may be a cytokine storm.

over 1 year ago

Journal

JAK2 (Janus kinase 2) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MAPK1 (Mitogen-activated protein kinase 1) • VEGFC (Vascular Endothelial Growth Factor C) • IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A) • PDGFA (Platelet Derived Growth Factor Subunit A) • PDGFB (Platelet Derived Growth Factor Subunit B) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • IL18BP (Interleukin 18 Binding Protein) • IL1R1 (Interleukin 1 receptor, type I) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • NFKBIA (NFKB Inhibitor Alpha 2) • STAT2 (Signal transducer and activator of transcription 2) • IL3 (Interleukin 3) • IL33 (Interleukin 33) • MAPK11 (Mitogen-Activated Protein Kinase 11) • MAPK12 (Mitogen-Activated Protein Kinase 12) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8) • MAPK9 (Mitogen-Activated Protein Kinase 9) • PDGFC (Platelet Derived Growth Factor C) • TNFAIP8 (TNF Alpha Induced Protein 8) • MAPK10 (Mitogen-Activated Protein Kinase 10)

over1year

ANXA5 predicts prognosis and immune response and mediates proliferation and migration in head and neck squamous cell carcinoma. (PubMed, Gene)

Through bioinformatics, a prognostic risk model of high precision was developed, offering valuable insights into the survival rates and immune responses in patients with HNSCC. ANXA5 is highlighted as a significant prognostic factor among the identified genes, indicating its promise as a potential therapeutic target for those with HNSCC.

over 1 year ago

Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MAPK1 (Mitogen-activated protein kinase 1) • CCR7 (Chemokine (C-C motif) receptor 7) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • ANXA5 (Annexin A5) • BAK1 (BCL2 Antagonist/Killer 1) • CRYAB (Crystallin Alpha B) • MAPK11 (Mitogen-Activated Protein Kinase 11)